Search
Presentation Details
| Evaluation of Compliance with Recommendation to Take Rivaroxaban with Food |
| Nghi Ha, Erin Mouland, Denise Sutter-Long, Anisa Bici, Liza Renner Michigan Medicine, Ann Arbor, MI, United States |
Introduction Rivaroxaban is a common anticoagulant use for the prevention of stroke in patients with atrial fibrillation (Afib) and in the prevention and treatment of thrombosis in patients with venous thromboembolism (VTE). Current recommendation requires that patient on rivaroxaban 15 mg or 20 mg daily take it with food, as food affects its absorption. Bioavailability for rivaroxaban 20 mg is estimated at 66% in a fasted state vs. high bioavailability (> 80%) with food. This study aims to assess the proportion of patients on rivaroxaban that is noncompliant with taking it with food. Methods A prospective study assessing the proportion of patients taking rivaroxaban without food. Patients on rivaroxaban 15 mg daily or 20 mg daily, for the indication of Afib or VTE, referred to an anticoagulation service for perioperative management between 6/2021-12/2024 were included. Rivaroxaban administration was assessed as part of the perioperative management process. Results A total of 641 patients were included in the analysis. Of those, 45 (7%) patients were not taking rivaroxaban with food. Majority of patients were taking rivaroxaban for Afib, 55%. There was a trend for higher proportion of noncompliance in patients with Afib vs. VTE, (8.6% vs. 5%, p = 0.07). Similar proportion of noncompliance was observed in patient managed by providers at Michigan Medicine vs. outside hospital regardless of specialty. Conclusion Approximately 7% of patient on rivaroxaban are not taking it with food, as recommended. Suboptimal absorption may result in suboptimal outcomes. Patients may benefit from reinforcement to take rivaroxaban with food. |